Thyroid Disorders Research Center, Arak University of Medical Sciences, Arak, Iran.
Diabetol Metab Syndr. 2013 Feb 26;5(1):8. doi: 10.1186/1758-5996-5-8.
Over the past decade, numerous non-skeletal diseases have been reported to be associated with vitamin D deficiency including type2 diabetes mellitus (T2DM). Different studies provide evidence that vitamin D may play a functional role in glucose tolerance through its effects on insulin secretion and insulin sensitivity. This study evaluates the effects of vitamin D supplementation on insulin resistance in T2DM.
Through a before-after study, 100 patients with T2DM, 30-70 years old, were recruited from an Arak diabetes clinic as consecutive attenders. Participants were assessed for clinical and biochemistry. Serum insulin and, 25(OH)D concentration, and HOMA-IR was calculated. All measurements were performed at the beginning and the end of the study. Patients received 50,000 unit of vitamin D3 orally per week for eight weeks, Statistical analysis was made using SPSS17. The results were analyzed by descriptive tests, and a comparison between variables were made using paired T-tests or Wilcoxon tests, as appropriate.
100 participants including 70 women (70%) and 30 men (30%) took part in the study. All results were presented as Mean±SD, or medians of non-normally distributed.24% of the participants were Vitamin D deficient {serum 25(OH)D ≤ 20 ng/ml(50 nmol/l)}.Mean serum 25 (OH) D concentration was 43.03± 19.28 ng/ml (107.5±48.2 nmol/l).The results at baseline and at the end, for FPG were 138.48±36.74 and 131.02±39 mg/dl (P=0.05), for insulin, 10.76±9.46 and 8.6±8.25 μIu/ml (P=0.028) and for HOMA-IR, 3.57±3.18 and 2.89±3.28 (P=0.008) respectively.
Our data showed significant improvements in serum FPG, insulin and in HOMA-IR after treatment with vitamin D, suggested that vitamin D supplementation could reduce insulin resistance in T2DM.
在过去的十年中,许多非骨骼疾病已被报道与维生素 D 缺乏有关,包括 2 型糖尿病(T2DM)。不同的研究表明,维生素 D 可能通过影响胰岛素分泌和胰岛素敏感性在葡萄糖耐量中发挥功能作用。本研究评估了维生素 D 补充对 T2DM 患者胰岛素抵抗的影响。
通过前后研究,从阿拉克糖尿病诊所招募了 100 名年龄在 30-70 岁的 T2DM 患者作为连续就诊者。评估参与者的临床和生化指标。检测血清胰岛素和 25(OH)D 浓度,并计算 HOMA-IR。所有测量均在研究开始和结束时进行。患者每周口服 50,000 单位维生素 D3,持续 8 周。使用 SPSS17 进行统计分析。使用描述性检验分析结果,并使用配对 T 检验或 Wilcoxon 检验(视情况而定)比较变量之间的差异。
共有 100 名参与者(70%为女性,30%为男性)参加了这项研究。所有结果均以均数±标准差或非正态分布的中位数表示。24%的参与者存在维生素 D 缺乏(血清 25(OH)D ≤ 20ng/ml[50nmol/l])。平均血清 25(OH)D 浓度为 43.03±19.28ng/ml(107.5±48.2nmol/l)。基线和结束时 FPG 的结果分别为 138.48±36.74 和 131.02±39mg/dl(P=0.05),胰岛素分别为 10.76±9.46 和 8.6±8.25μIU/ml(P=0.028),HOMA-IR 分别为 3.57±3.18 和 2.89±3.28(P=0.008)。
我们的数据表明,维生素 D 治疗后血清 FPG、胰岛素和 HOMA-IR 显著改善,提示维生素 D 补充可降低 T2DM 患者的胰岛素抵抗。